Active Not Recruiting PHASE2 INTERVENTIONAL 3-arm
NCT06623539
Efficacy and Safety of Pemafibrate for Nonalcoholic Fatty Liver Disease
Pemafibrate for Treating NAFLD Complicated by Hypertriglyceridemia: A Multi-center, Open Study, Randomized Controlled Trial (PRESENT Study)
Sponsor: Yokohama City University
Conditions
Non Alcoholic Fatty Liver Disease
Interventions
Fenofibrate Pemafibrate high dose Pemafibrate low dose
Updated 1 time since 2024 Last updated: Oct 1, 2024 Started: Dec 23, 2020 Primary completion: Jun 30, 2025 Completion: Mar 31, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
A PHASE2 clinical study on Non Alcoholic Fatty Liver Disease, this trial is ongoing. The trial is conducted by Yokohama City University and has accumulated 1 data snapshot since 2020. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
1 version recorded Active Not Recruiting — PHASE2
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Yokohama City University
Data source: Yokohama City University
For direct contact, visit the study record on ClinicalTrials.gov .